Recently, Shanghai Lktime Biotech and Dartsbio (Guangdong) have officially signed an agreement, where both parties have reached a strategic cooperation on the full lifecycle of bio-macromolecule drug discovery, process development and quality research, and commercial manufacturing of drugs. Dartsbio (Guangdong) will complete the subsequent IND application and commercial production of bio-macromolecule projects through Lktime Biotech' CMC platform.

Dartsbio (Guangdong) is a leading antibody research and development company in the industry. The company upholds the mission of enhancing the quality of human life and adheres to the vision of "conquering diseases and improving the quality of life". It focuses deeply on the field of innovative antibody drugs for the treatment of pain and oncological complications, providing new ideas for addressing significant clinical needs that have not yet been met.

Shanghai Lktime Biotech is an innovative CDMO company with both eukaryotic and prokaryotic dual expression platforms, offering one-stop biopharmaceutical R&D and production services. It is primarily dedicated to providing end-to-end CDMO services for bio-macromolecule drugs such as antibody drugs and recombinant protein drugs, from target development to commercial production. Since its establishment, adhering to the principle of "customer first, service paramount", it has consistently implemented the philosophy of providing clients with high-level and high-quality drug R&D and production services, empowering global partners, accelerating the commercialization process of drugs, and benefiting a wide range of patients.

Dr. Wang Chunhe, the founder and chairman of Dartsbio (Guangdong), said: "I am very pleased to reach a strategic cooperation with Shanghai Lktime Biotech. Since its establishment, Dartsbio (Guangdong) has adhered to a 'differentiated innovation' strategy, forming a distinctive R&D product pipeline. Several projects are entering the clinical stage one after another. Shanghai Lktime Biotech, as a biopharmaceutical CDMO technology service platform, has rich experience in drug discovery, preclinical process development, and commercial production. The professional complementarity with the Dartsbio (Guangdong) team is highly compatible. I look forward to working hand in hand with the Lktime team to jointly create a new ecosystem for domestic innovative drugs."